Company / Total Debt
ANI Pharmaceuticals, Inc. Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$291.8M
FY2025
5-year range
$284.8M / $309.1M
FY2021-FY2025
Trend
-5.6%
vs FY2024
Sector context
#36 of 83
Health Care
What the data says
At $292M, ANI Pharmaceuticals, Inc.'s total debt ranks #48 of 83 in the Health Care sector. Total Debt has fluctuated over the past 10 years, ranging from $67M in FY2018 to $309M in FY2024.
Based on SEC 10-K filings.
$292M in FY2025 with a 5-year CAGR of +11.1%.
Increased from $285M to $292M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +0.7%
- 5-Year CAGR
- +11.1%
- 10-Year CAGR
- -
Sector benchmark
#48 of 83 in Health CareTop 57% of 83This company $291.8M Sector average $6.2B
▼
-95.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.1%, indicating consistent growth.
- In FY2025, total debt decreased 5.6% year-over-year.
- Ranks #36 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $291.8M | -5.6% |
| FY2024 | $309.1M | +8.5% |
| FY2023 | $284.8M | -0.3% |
| FY2022 | $285.7M | -0.3% |
| FY2021 | $286.5M | +66.2% |
| FY2020 | $172.4M | -1.9% |
| FY2019 | $175.8M | +161.2% |
| FY2018 | $67.3M | -47.5% |
| FY2017 | $128.2M | +6.3% |
| FY2016 | $120.6M | +6.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026